Aristotle Capital Management LLC Sells 153,136 Shares of Amgen Inc. $AMGN

Key Points

• Aristotle Capital Management lowered its stake in Amgen by 4.2%, selling 153,136 shares and now holds 3,474,491 shares (about $980.5 million or 0.65% of Amgen).
• Amgen posted a quarterly EPS beat ($5.29 vs. $4.76 expected) and revenue of $9.87B, set FY2026 guidance of 21.60–23.00 EPS, and announced a quarterly dividend of $2.52 (annualized $10.08, ~2.8% yield).
• The company has a market cap near $197B with ~76.5% institutional ownership; analysts have a consensus "Hold" rating (target ~$354) amid positive distribution and product momentum but lingering concerns over debt levels and dividend attractiveness.

Aristotle Capital Management LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,474,491 shares of the medical research company's stock after selling 153,136 shares during the period. Amgen makes up 1.9% of Aristotle Capital Management LLC's portfolio, making the stock its 18th largest holding. Aristotle Capital Management LLC owned 0.65% of Amgen worth $980,528,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AMGN. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen in the second quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC bought a new stake in Amgen in the 3rd quarter valued at $34,000. AXS Investments LLC bought a new stake in Amgen in the 3rd quarter valued at $42,000. Finally, Winnow Wealth LLC acquired a new position in Amgen in the 3rd quarter valued at $47,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $366.21 on Friday. The company has a market cap of $197.41 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 3.63 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a fifty day moving average price of $357.73 and a 200-day moving average price of $325.42.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen's revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AMGN shares. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an "outperform" rating in a research report on Thursday, January 29th. Citigroup boosted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a research report on Wednesday, February 4th. Wall Street Zen lowered shares of Amgen from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price objective for the company. Finally, Argus boosted their price objective on shares of Amgen from $360.00 to $400.00 and gave the company a "buy" rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $354.00.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen NASDAQ: AMGN Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis - Amgen, Inc.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.